Utility Menu

National Association of Pharmacy Regulatory Authorities

Provinces

Main navigation


Search: National Drug Schedules

Begin your search by using the generic name of the product:

Search by Glossary
Drug Name Comment Schedule Date
Abacavir or its saltsPDL I DEC / 13
AbataceptPDL I DEC / 13
AbciximabPDL I DEC / 13
Abiraterone or its derivativesPDL

including but not limited to abiraterone acetate

I DEC / 13
Acamprosate or its saltsPDL I DEC / 13
Acarbose or its derivativesPDL I DEC / 13
Acebutolol or its saltsPDL I DEC / 13
Acepromazine or its saltsPDL

for human use

I DEC / 13
AcetaminophenPDL

when recommended for administration by intravenous injection

I DEC / 13
Acetaminophen in sustained release formulations

up to and including 650 mg per unit, in package sizes containing no more than 50 units

U JAN / 03
Acetaminophen in sustained release formulations.

in strengths of greater than 650 mg per unit or in package sizes of more than 50 units

III JAN / 03
Acetaminophen. in immediate release tablets, capsules, suppositories or liquid U SEP / 99
AcetanilidePDL

for human use

I DEC / 13
Acetarsol II SEP / 98
AcetazolamidePDL I DEC / 13
AcetohexamidePDL I DEC / 13
AcetorphineN I JUN / 02
Acetyl-a-methylfentanylN I JUN / 02
AcetylcarbromalPDL I DEC / 13
Acetylcholine ChloridePDL I DEC / 13
Acetylcysteine II SEP / 98
AcetyldihydrocodeineN I JUN / 02
AcetylmethadolN I JUN / 02
Acetylsalicylic acid and its salts oral preparations containing 80 mg or less per dosage unit and intended for pediatric use or rectal preparations containing 150 mg or less per dosage unit, in package sizes containing no more than 1.92 g of acetylsalicylic acid. II FEB / 02
Acetylsalicylic acid and its salts. in products for oral use in strengths of 325mg and 500mg per dosage unit U OCT / 00
Acetylsalicylic acid and its salts.. in products intended for oral adult use in strengths of 81 mg per dosage unit and 650 mg or greater per dosage unit, and in rectal preparations containing more than 150 mg per dosage unit III OCT / 00
Acitretin or its salts or derivativesPDL I DEC / 13
Aclidinium or its saltsPDL I DEC / 13
Aconiazide or its saltsPDL I DEC / 13
Acyclovir or its saltsPDL I DEC / 13
AdalimumabPDL I DEC / 13
Adapalene or its salts or derivativesPDL I DEC / 13
Adefovir or its salts or derivativesPDL

including but not limited to adefovir dipivoxil

I DEC / 13
Adenosine or its saltsPDL

when sold or recommended for administration by intravenous injection

I DEC / 13
Adiphene and its salts for parenteral use II SEP / 98
Adrenocortical hormones or their salts or derivativesPDL

for human use including but not limited to: Betamethasone valerate, betamethasone sodium, betamethasone phosphate, betamethasone dipropionate, budesonide, ciclesonide, clobetasone, cortisone, dexamethasone sodium, dexamethasone phosphate, dexamethasone acetate, difluprednate, fludrocortisone acetate, flunisolide, fluticasone propionate, fluticasone furoate, hydrocortisone acetate, hydrocortisone aceponate, hydrocortisone sodium, methylprednisolone acetate, methylprednisolone, methylprednisolone succinate, methylprednisolone sodium, mometasone furoate, prednisolone acetate, prednisolone sodium, prednisolone phosphate, prednisone, triamcinolone acetonide, triamcinolone hexacetonide except: (a) hydrocortisone or hydrocortisone acetate, when sold as a single medicinal ingredient in a concentration that provides 1.0% or less hydrocortisone in preparations for topical use on the skin; or (b) hydrocortisone or hydrocortisone acetate, when sold in combination with any other nonprescription medicinal ingredient that provides 1.0% or less hydrocortisone in preparations for topical use on the skin; or (c) clobetasone butyrate when sold in a concentration of 0.05% in cream preparations for topical use on the skin; or (d) triamcinolone acetonide in a nasal spray that delivers 55 microgram (mcg)/spray for those 12 years of age and older; or, (e) mometasone furoate for the treatment of allergic rhinitis in a nasal spray that delivers 50 mcg/spray for those 12 years of age and older; or (f) fluticasone propionate for the treatment of allergic rhinitis in a nasal spray that delivers 50 microgram/spray for those 18 years of age and older.

I AUG / 16
Afatinib or its saltsPDL I DEC / 13
AfliberceptPDL I DEC / 13
AfoxolanerPDL I AUG / 14
Agalsidase AlfaPDL I APR / 07
Agalsidase BetaPDL I DEC / 14
AlbiglutidePDL I AUG / 15
AldesleukinPDL I DEC / 13
Alectinib or its saltsPDL I NOV / 16
AlefaceptPDL I DEC / 13
AlemtuzumabPDL I DEC / 13
Alendronic acid or its saltsPDL I DEC / 13
AlfacalcidolPDL I DEC / 13
AlfentanilN I JUN / 02
Alfuzosin or its saltsPDL I DEC / 13
Alglucosidase alfaPDL I DEC / 13
AlirocumabPDL I AUG / 16
Aliskiren or its saltsPDL I DEC / 13
Alitretinoin or its salts or derivativesPDL I DEC / 13
Alkyl nitritesPDL I DEC / 13
Allergy serums and extracts I SEP / 99
Allethrins II SEP / 98
AllobarbitalC2 I JUN / 02
AllopurinolPDL I DEC / 13
AllylisopropylacetylureaPDL I DEC / 13
AllylprodineN I JUN / 02
Almotriptan or its saltsPDL I DEC / 13
Aloe vera latex, its extracts and derivatives[except aloin] dosage forms for systemic use containing more than 300 mg per dosage unit III SEP / 98
Alogliptin or its salts or its derivativesPDL I DEC / 13
Aloin U
Alpha-chloralosePDL I DEC / 13
Alpha-hydroxy acidsPDL

including but not limited to citric acid, glycolic acid, lactic acid, malic acid, mandelic acid, ammonium glycolate, glycolic acid + ammonium glycolate, alpha-hydroxyethanoic acid + ammonium alpha-hydroxyethanoate, alpha-hydroxyoctanoic acid, alpha-hydroxycaprylic acid, hydroxycaprylic acid, mixed fruit acid, triple fruit acid, tri-alpha hydroxy fruit acids, alpha hydroxy and botanical complex, l-alpha hydroxy acid, glycomer in cross-linked fatty acids alpha nutrium, when sold in topical formulations containing alpha hydroxy acids alone or in combination at concentrations of greater than 30% and/or with a pH lower than 3.0, except when sold to be applied to warts, corns or calluses

I DEC / 14
AlphacetylmethadolN I JUN / 02
Alphadolone or its saltsPDL I DEC / 13
AlphameprodineN I JUN / 02
AlphamethadolN I JUN / 02
AlphaprodineN I JUN / 02
AlphaxalonePDL

including but not limited to alfaxalone, alphaxolone

I DEC / 13
AlphenalC2 I JUN / 02
AlprazolamTS I SEP / 98
Alteplase or its salts or derivativesPDL

including but not limited to tenecteplase

I DEC / 13
AltrenogestPDL I DEC / 13
AltretaminePDL I DEC / 13
Aluminum oxide III SEP / 98
Alverine and its salts for parenteral use I SEP / 98
Amantadine or its saltsPDL I DEC / 13
Ambenonium ChloridePDL I DEC / 13
AmbrisentanPDL I DEC / 13
Amifostine or its saltsPDL I DEC / 13
Amikacin or its salts or derivativesPDL

PDL, including but not limited to amikacin sulfate

I DEC / 13
Amiloride or its saltsPDL I DEC / 13
Amino Acid solutions for parenteral use I SEP / 99
Amino-pteroyl aspartic acid or its saltsPDL I DEC / 13
Aminocaproic acidPDL I DEC / 13
AminoglutethimidePDL I DEC / 13
Aminolevulinic acid or its salts or derivativesPDL I DEC / 13
AminophyllinePDL I DEC / 13
Aminopromazine [proquamezine] and its salts I SEP / 98
Aminopterin or its salts or derivativesPDL I DEC / 13
Aminopyrine or its derivativesPDL

for human use

I DEC / 13
Aminorex and any salt thereofC4 I JAN / 03
Aminosalicylic Acid or its saltsPDL I DEC / 13
Aminosalicylic acidPDL

including but not limited to mesalazine

I DEC / 13
Amiodarone or its salts or derivativesPDL

including but not limited to dronedarone

I DEC / 13
AmitrazPDL I DEC / 13

1882 result(s)


Footnotes

  • C1: Drug is in the Controlled Drugs and Substances Act and Part I of the Schedule to Part G of the Food and Drug Regulations}
  • C2: Drug is in the Controlled Drugs and Substances Act and Part II of the Schedule to Part G of the Food and Drug Regulations
  • C3: Drug is in the Controlled Drugs and Substances Act and Part III of the Schedule to Part G of the Food and Drug Regulations
  • C4: drug is in the Controlled Drugs and Substances Act
  • C5: drug is in the Regulations Under CDSA
  • CR: drug has been recommended for addition to the Controlled Drugs and Substances Act
  • CR-C: drug has been recommended for addition to the Controlled Drugs and Substances Act, Part G of the Food and Drug Regulations
  • CR-N: drug has been recommend for addition to the Controlled Drugs and Substances Act, Narcotic Control Regulations
  • CR-TS: drug has been recommended for addition to the Controlled Drugs and Substances Act, Benzodiazepines and Other Targeted Substances Regulations
  • F1: drug appears in Part I of Schedule F to the Food and Drugs Act and Regulations
  • F2: drug appears in Part II of Schedule F to the Food and Drugs Act and Regulations
  • FR: drug has been recommended for addition to Schedule F to the Food and Drugs Act and Regulations ("Schedule F Recommended")
  • N: drug is in the Narcotic Control Regulations under the Controlled Drugs and Substances Act
  • NR: drug has not been reviewed by NDSAC
  • PDL: drug is in the Prescription Drug List (effective Dec. 19, 2013)
  • R: drug is in Part J of the Food and Drus Act and listed in the Controlled Drugs and Substances Act
  • TS: drug is in the Benzodiazepines and Other Targeted Substances Regulations under the Controlled Drugs and Substances Act
  • U: drug has been reviewed by NDSAC and is unscheduled